The continuous optimization and development of CAR-T cell therapy has brought great hope for the treatment of hematological malignancies, and great progress has been made so far. However, acute Graft-versus-Host Disease (GVHD) has been found in the study and application of CAR-T cell therapy, which has hindered the development of CAR-T cell therapy. GVHD is a major complication of allogeneic transplantation, which is caused by T lymphocytes in the allogeneic donor graft attacking allotypic antigens in the recipient after transplantation, resulting in a series of adverse reactions and even death.
GemPharmatech has developed and validated two mouse models for studying and evaluating the efficacy of anti-GVHD drugs.